Biotechnology start-ups and pharmaceutical giants alike are charging ahead to develop therapies for the most serious form of non-alcoholic fatty liver disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
La stéatopathie dysmétabolique
Schweizer Gastroenterologie Open Access 21 September 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional information
This article is part of Nature Outlook: Fatty liver disease, an editorially independent supplement produced with the financial support of third parties. About this content.
Rights and permissions
About this article
Cite this article
Drew, L. Drug development: Sprint finish. Nature 551, S86–S89 (2017). https://doi.org/10.1038/d41586-017-06926-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/d41586-017-06926-1
This article is cited by
-
La stéatopathie dysmétabolique
Schweizer Gastroenterologie (2020)
-
Mechanisms of NAFLD development and therapeutic strategies
Nature Medicine (2018)
